INSULIN GLP-1 COMBINATIONS
Soliqua (insulin glargine and lixisenatide),
Xultophy (insulin degludec and liraglutide)

RATIONALE FOR INCLUSION IN PA PROGRAM

Background
Soliqua and Xultophy are injectable antidiabetic agents containing a long-acting human insulin
analog (insulin glargine or degludec) and glucagon-like peptide-1 (GLP-1) receptor agonists
(lixisenatide or liraglutide). Soliqua and Xultophy are indicated for adults with type 2 diabetes
mellitus who have had a suboptimal response to other diabetic agents. Long acting insulin acts via
specific membrane-bound receptors on the liver, skeletal muscle, and adipose tissue to regulate
metabolism of carbohydrates, proteins, and fats. GLP-1 receptor agonists effects post-prandial
blood glucose by binding to the same receptors as endogenous hormone incretin leading to
increased glucose-dependent insulin secretion, decreased inappropriate glucagon release, and
slowed gastric emptying (1-2).

Regulatory Status
FDA-approved indication:

Soliqua
Soliqua is a combination of a long-acting human insulin analog with a glucagon-like peptide-1
(GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control
in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units
daily) or lixisenatide (1).

Xultophy
Xultophy is a combination of insulin degludec, a long-acting human insulin analog, and liraglutide,
a glucagon-like peptide 1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to
improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal
insulin (less than 50 units daily) or liraglutide (2).

Limitations of Use: (1-2)
1. Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis
2. Not recommended for use in combination with any other product containing a GLP-1
   receptor agonists or basal insulin
3. Not recommended for use in patients with gastroparesis
INSULIN GLP-1 COMBINATIONS
Soliqua (insulin glargine and lixisenatide),
Xultophy (insulin degludec and liraglutide)

4. Has not been studied in people taking short-acting (prandial) insulin
5. Has not been studied in patients with a history of unexplained pancreatitis

Xultophy has a boxed warning and contraindication in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 are at high risk of treatment duration-dependent thyroid C-cell tumors. Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC. Significantly elevated serum calcitonin may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated (2).

The safety and effectiveness of Soliqua and Xultophy have not been established in patients under 18 years of age (1-2).

Summary
Soliqua and Xultophy are injectable combination products indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (1-2). The two active ingredients in Soliqua and Xultophy work to control fasting and post-prandial glucose by regulating carbohydrate metabolism. Long acting insulin acts via specific membrane-bound receptors on the liver, skeletal muscle, and adipose tissue. GLP-1 receptor agonists bind to the same receptors as endogenous hormone incretin leading to increased glucose-dependent insulin secretion, decreased inappropriate glucagon release, and slowed gastric emptying. The safety and effectiveness of Soliqua and Xultophy have not been established in patients under 18 years of age (1-2).

Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Soliqua and Xultophy while maintaining optimal therapeutic outcomes.

References
INSULIN GLP-1 COMBINATIONS
Soliqua (insulin glargine and lixisenatide),
Xultophy (insulin degludec and liraglutide)